Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation
Brief Description Of Study
The GLORIA-AF Registry Program consists of three phases and is an observational study. It is designed to characterize newly diagnosed patients with non-valvular atrial fibrillation at risk for stroke in different regions of the world and to describe current patterns of antithrombotic treatments selected at the patients baseline visit. The baseline visit of each phase is defined as the visit in which the patient is enrolled into the registry. In addition, safety data and outcomes of such patients will be collected in Phase II and III of the Registry program. Phase I is described in a separate protocol and is only related to the pre-approval time. The present protocol describes the combined Phase II and III of the GLORIA-AF Registry Program. In each phase newly diagnosed non-valvular AF patients at risk of stroke, as characterized by a CHA2DS2-VASc score of at least 1 are planned to be included. This is an observational study, which means it is a study that does not prescribe specific medication or require procedures outside of usual medical care.